TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Design Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Renee Leck
Design Therapeutics to Participate in Upcoming Investor Conferences

Design Therapeutics plans to initiate patient dosing for DT-818, a potential treatment for Myotonic Dystrophy Type-1, in the first half of 2026. The company has obtained ex-US regulatory clearance and is developing gene-targeted therapies for various genetic diseases.

Insights
GBFH   neutral

The company maintains stability despite the departure of a founding director, with no indication of internal disruption


DSGN   positive

Company is advancing multiple clinical-stage programs, obtaining regulatory clearances, and expanding its genomic medicine research, indicating positive growth and development potential